Drug intelligence / Profile preview

afuresertib + abiraterone

Development stage: Unknown
Lead developer: Laekna
Modality: Small Molecules
Administration: Oral

Overview

**Afuresertib + abiraterone** is a drug combination being investigated for the treatment of metastatic castration-resistant prostate cancer (mCRPC). Afuresertib is a small molecule inhibitor of AKT1, AKT2, and AKT3, crucial components of the PI3K/AKT/PTEN signaling pathway, which is implicated in therapy resistance in prostate cancer. Abiraterone is an androgen biosynthesis inhibitor that blocks CYP17A1, reducing androgen production and thereby inhibiting androgen receptor signaling, a key driver of prostate cancer progression. Combined, these drugs act through dual mechanisms: suppressing PI3K/AKT pathway signaling and blocking androgen biosynthesis, potentially overcoming resistance to hormone-targeted therapies.

Brand names: Zytiga (for abiraterone)
Other names: afuresertib + abiraterone

Targets

AKT2 (Rac-beta serine/threonine-protein kinase)AKT1 (Proto-oncogene serine/threonine-protein kinase Akt1)CYP17A1 (Steroid 17-alpha-hydroxylase/C17,20 lyase)

Beyond the preview

Go deeper on afuresertib + abiraterone.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on afuresertib + abiraterone.

Explore the full profile